Page last updated: 2024-09-05

enzastaurin and Genetic Predisposition

enzastaurin has been researched along with Genetic Predisposition in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Brody, J; Cao, J; Han, I; Heineman, T; Jing, H; Jivani, M; Lansigan, F; Li, L; Liu, Y; Lue, JK; Luo, W; Maly, J; Nowakowski, GS; Rizvi, S; Smith, SD; Song, Y; Sun, J; Sun, X; Zhang, L; Zhang, Q; Zhu, J	1

Trials

1 trial(s) available for enzastaurin and Genetic Predisposition

Article	Year
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1. Future oncology (London, England), 2020, Volume: 16, Issue:15 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Vincristine	2020

Article

Year

ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.

Future oncology (London, England), 2020, Volume: 16, Issue:15

Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Doxorubicin; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Indoles; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Research Design; Rituximab; Vincristine

2020